Ipsen: Specialty Pharma and External Innovation

Ipsen faced the nightmare of every drug company — its biggest product heading toward patent expiry — and answered not by inventing its way out alone, but by shopping for the future. Through disciplined licensing and acquisition, this focused specialty pharma rebuilt its pipeline and returned to strong growth. This article explains what specialty pharma is, how the external-innovation model works, and why focus and dealmaking define Ipsen.

Ipsen’s story is a useful counterpoint to the giants of its industry. Where a Sanofi can afford to spend billions hunting for blockbusters across many diseases, a company a tenth its size must be cleverer than it is big — choosing its battles narrowly and buying in the innovation it cannot generate alone. How it does so illuminates the strategy of specialty pharma everywhere.

What is Ipsen and what does it do?

Ipsen is a French specialty biopharmaceutical company — meaning it focuses on particular therapeutic areas rather than trying to cover all of medicine like the largest ‘big pharma’ groups. It concentrates on three carefully chosen fields: oncology (cancer), rare diseases, and neuroscience, developing and selling targeted medicines for often serious, complex or hard-to-treat conditions where patients have few good options.

With €3.4 billion in 2024 sales, Ipsen is far smaller than a giant like Sanofi, but it is a significant player, ranking among the world’s top 15 companies in oncology sales. Its long-established products include Somatuline (for neuroendocrine tumours and a hormonal disorder) and Dysport (a botulinum-toxin used in both neurology and aesthetics), alongside a growing range of newer cancer, liver-disease and rare-disease drugs added through recent deals.

Ipsen’s strategy is built on focus and agility: as a mid-sized company it cannot outspend big pharma on research across every disease, so it concentrates its resources on chosen niches where it can build real expertise and leadership. Understanding how it competes despite its size — chiefly through external innovation — is the key to the company.

What is the ‘external innovation’ model?

‘External innovation’ is Ipsen’s central strategy of sourcing new medicines from outside its own laboratories — by licensing the rights to promising experimental drugs from smaller biotech firms, or acquiring those firms outright — rather than relying solely on internal research to discover them. It effectively lets Ipsen ‘buy in’ innovation to fill and refresh its pipeline.

This model suits a mid-sized specialty company perfectly. Much of the most exciting early-stage drug science happens in small, focused biotechs that have promising molecules but lack the money, scale or commercial reach to develop and sell them globally. Ipsen partners with or acquires these firms, then applies its development expertise, regulatory know-how and sales network to turn their science into approved, marketed medicines.

The advantage is speed and efficiency: instead of gambling everything on the slow, uncertain output of its own labs, Ipsen can select from the best externally-developed candidates, spreading its bets and adding proven, de-risked assets. Deals in recent years — licensing cancer drugs like cabozantinib (Cabometyx), and acquiring rare-disease and liver-disease treatments through targeted acquisitions — show the model in action, and it is how Ipsen rebuilt its future.

Crucially, external innovation is a two-way relationship, not merely a shopping trip. Small biotechs actively seek partners like Ipsen because they need exactly what Ipsen offers — the money to fund expensive late-stage trials, the expertise to navigate regulators, and the sales network to reach doctors worldwide. By being a reliable, knowledgeable partner in chosen fields, Ipsen makes itself an attractive home for others’ science, which in turn improves the quality of the deals it can access. Reputation as a good developer thus becomes a competitive advantage in the race to license the best molecules.

Why did Ipsen need to rebuild its pipeline?

Ipsen faced a classic pharma challenge: heavy dependence on a single ageing product, Somatuline, which faced eventual patent expiry and generic competition that would erode its sales. Like any drugmaker staring at a ‘patent cliff,’ Ipsen had to find new products to replace that revenue or risk decline — and it had to do so relatively quickly.

Rather than wait for its own labs to deliver, Ipsen turned decisively to external innovation, striking a series of licensing deals and acquisitions to bring in new oncology, rare-disease and neurology medicines. This diversified its revenue across many products, steadily reducing its reliance on any single medicine and giving it multiple independent growth drivers. By 2024 the strategy was clearly working: all three of its therapeutic areas grew, with the rare-diseases portfolio surging by more than two-thirds, and total sales rising nearly 10%.

The turnaround shows the external-innovation model as a survival tool. Confronted with the loss of its biggest earner, Ipsen used dealmaking to rebuild a broader, more resilient portfolio faster than internal research alone could have — transforming a looming crisis into renewed growth, and proving a mid-sized specialist can thrive by being a smart buyer of innovation, not only an inventor of it.

Why is Ipsen so profitable for its size?

Despite its modest scale, Ipsen is strikingly profitable, with a core operating margin above 30% in 2024 — a level that reflects the economics of focused specialty pharma. By concentrating on selected high-value medicines for serious conditions, often with limited competition, Ipsen commands strong pricing and needs a smaller commercial footprint than a mass-market drug company.

Specialty medicines — for cancers, rare diseases and specific neurological needs — are typically prescribed by a relatively small number of specialist doctors, so a company can reach its market with a compact, expert sales force rather than a vast one. This keeps costs down while prices and margins stay high, because the drugs address serious unmet needs. A good illustration is Dysport, Ipsen’s botulinum-toxin product, which earns revenue in both therapeutic neurology (treating conditions like muscle spasticity) and aesthetics — a versatile, high-margin asset that spans medical and cosmetic uses. This blend of focus, pricing power and efficiency is what lets a mid-sized company like Ipsen generate profitability that rivals far larger groups.

How does family control shape Ipsen?

Ipsen is publicly listed but controlled by the founding Beaufour family, through their holding company Mayroy, which holds a majority of the shares. The company traces its roots to 1929, and this long family ownership gives Ipsen a stable, long-term orientation unusual in the fast-moving, often takeover-prone pharmaceutical industry.

Family control provides continuity and patience — valuable in pharma, where drug development and pipeline-building play out over many years and reward owners who can look beyond the next quarter. It also shields Ipsen from hostile takeover, letting management pursue its focused, deal-driven strategy without the constant threat of being swallowed by a larger rival. This family stewardship places Ipsen alongside the many family-controlled champions across the France Company Stories hub, applying the model to specialty medicine.

At the same time, being listed subjects Ipsen to market discipline and gives it access to capital and an acquisition currency. The blend — family stability plus public accountability — has supported a company confident and secure enough to reshape its own portfolio decisively when its biggest product came under threat, rather than being forced into a hasty sale or merger.

What are the risks facing Ipsen?

As a specialty pharma, Ipsen’s focus is both a strength and a risk: concentration in a few therapeutic areas and a relatively small number of key products means a setback to any one — a safety issue, a failed trial, faster-than-expected generic erosion — can hit hard. Its reliance on external innovation also carries risk, as licensing and acquisitions can be expensive and may not always deliver.

Ipsen faces the industry-wide pressures of drug-pricing scrutiny, tough regulation, and competition from larger, better-resourced rivals in oncology and beyond. Integrating acquired products and companies, sustaining a full pipeline through continued dealmaking, and eventually replacing today’s growth drivers as they mature are perpetual challenges. Its smaller scale, while enabling sharp focus, leaves less room for error than a diversified giant enjoys, so each strategic decision carries greater weight.

What can founders learn from Ipsen?

Ipsen shows that you do not have to invent everything yourself to build a successful innovation business. By systematically sourcing promising science from outside — licensing and acquiring drugs from smaller biotechs and scaling them with its own expertise — Ipsen competes effectively against far larger rivals, turning dealmaking into a core capability rather than an occasional tactic.

It also demonstrates the value of focus for a smaller player: by concentrating on a few therapeutic areas rather than chasing every opportunity, Ipsen builds the depth, expertise and leadership it could never achieve by spreading itself thin across all of medicine. And its patient-family ownership gave it the stability to reshape its portfolio boldly when threatened. For anyone studying the France Company Stories hub, Ipsen is the case study in the external-innovation model and focused specialty strategy — proof that being a smart, disciplined buyer and developer of others’ breakthroughs can be a winning path in a science-driven industry. Explore the pharma, diagnostics and cosmetics champions around it across the Pharma, Health & Cosmetics pillar.

Frequently Asked Questions